Cheryl Erwin

ORCID: 0000-0003-4223-457X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Genetic Neurodegenerative Diseases
  • Epigenetics and DNA Methylation
  • Neurological disorders and treatments
  • BRCA gene mutations in cancer
  • Ethics in medical practice
  • Disaster Response and Management
  • Birth, Development, and Health
  • Ethics and Legal Issues in Pediatric Healthcare
  • Ethics in Clinical Research
  • Diet and metabolism studies
  • Innovations in Medical Education
  • DNA Repair Mechanisms
  • Empathy and Medical Education
  • History of Medical Practice
  • Parkinson's Disease Mechanisms and Treatments
  • Public Health Policies and Education
  • Global Security and Public Health
  • Prenatal Substance Exposure Effects
  • Opioid Use Disorder Treatment
  • Discrimination and Equality Law
  • Cancer-related gene regulation
  • Metabolism and Genetic Disorders
  • Neurological diseases and metabolism
  • Bacillus and Francisella bacterial research
  • Health, Environment, Cognitive Aging

Texas Tech University
2014-2023

Texas Tech University Health Sciences Center
2014-2023

Lubbock Christian University
2014

Cal Humanities
2009-2012

Leavitt Partners (United States)
2009

The University of Texas at Austin
2008

The University of Texas Health Science Center at Houston
2007

J.-M. Lee E.M. Ramos J.-H. Lee Tammy Gillis Jayalakshmi Srinidhi Mysore and 95 more Michael R. Hayden Simon C. Warby PJ Morrison Martha Nance Christopher A. Ross Russell L. Margolis Ferdinando Squitieri S. Orobello Stefano Di Donato Estrella Gómez‐Tortosa Carmen Ayuso Oksana Suchowersky R J Trent Elizabeth McCusker Andrea Novelletto Marina Frontali Randi Jones Tetsuo Ashizawa Samuel Frank Marie Saint‐Hilaire Steven M. Hersch H. Diana Rosas Diane Lucente Madeline Harrison Andrea Zanko Ruth K. Abramson Karen Marder Jorge Sequeiros Jane S. Paulsen G. Bernhard Landwehrmeyer Richard H. Myers Marcy E. MacDonald James F. Gusella Alexandra Dürr Adam Rosenblatt Luigi Frati Susan B. Perlman P. M. Conneally Mary Lou Klimek Melissa Diggin Tiffany C. Hadzi Ayana Duckett Anwar Ahmed Paul Allen David Ames Thomas Anderson Karla J. Anderson Karen Anderson Thomasin Andrews John Ashburner Eric Axelson Elizabeth Aylward Roger A. Barker Katrin Barth Stacey K. Barton Kathleen Baynes Alexandra Bea Erik B. Beall Mirza Faisal Beg Leigh J. Beglinger Kevin Biglan K. Björk Steve Blanchard Jeremy Bockholt Sudharshan Reddy Bommu Bradley G. Brossman Maggie Burrows Vince D. Calhoun Noelle E. Carlozzi Amy M. Chesire Edmond Chiu Phyllis Chua R.J. Connell Carmela Connor Jody Corey‐Bloom David Craufurd Stephen Cross Lucette A. Cysique Rachelle Dar Santos Jennifer Davis Joji Decolongon A. Dipietro Nicholas Doucette Nancy R. Downing Ann Dudler Steve Dunn Daniel Ecker Eric A. Epping Diane Erickson Cheryl Erwin Kenneth Evans Stewart A. Factor Sarah Tomaszewski Farias Marta Fatas Jess G. Fiedorowicz

<h3>Objective:</h3> Age at onset of diagnostic motor manifestations in Huntington disease (HD) is strongly correlated with an expanded CAG trinucleotide repeat. The length the normal repeat allele has been reported also to influence age onset, interaction allele. Due profound implications for mechanism and modification, we tested whether allele, between alleles, or presence a second affects HD signs. <h3>Methods:</h3> We modeled natural log-transformed as function lengths alleles their by...

10.1212/wnl.0b013e318249f683 article EN Neurology 2012-02-09

There is growing consensus that intervention and treatment of Huntington disease (HD) should occur at the earliest stage possible. Various early-intervention methods for this fatal neurodegenerative have been identified, but preventive clinical trials HD are limited by a lack knowledge natural history dearth appropriate outcome measures. Objectives current study to document premanifest progression in largest cohort ever studied develop battery imaging markers can be used as measures trials....

10.3389/fnagi.2014.00078 article EN cc-by Frontiers in Aging Neuroscience 2014-04-22

The COVID-19 pandemic has raised a host of ethical challenges, but key among these been the possibility that health care systems might need to ration scarce critical resources. Rationing policies for pandemics differ by institution, system, and applicable law. Most seem agree patient's ability benefit from treatment survive are first-order considerations. However, there is debate about what clinical measures should be used make determination other factors ethically appropriate consider. In...

10.1080/15265161.2020.1764138 article EN other-oa The American Journal of Bioethics 2020-06-08

Alcoholism has a profound impact on millions of people throughout the world. However, ability to determine if patient needs treatment is hindered by reliance self-reporting and clinician's capability monitor patient's response challenged lack reliable biomarkers. Using genome-wide approach, we have previously shown that chronic alcohol use associated with methylation changes in DNA from human cell lines. In this pilot study, now examine peripheral mononuclear gathered subjects as they enter...

10.4161/epi.32252 article EN Epigenetics 2014-08-11

Abstract Potential discrimination from genetic testing may undermine technological advances for health care. Researching long‐term consequences of conditions that lead to is a public priority. The generate social, health, and economic burdens society by diminishing opportunities at‐risk individuals in range contexts. current study objective was investigate perceptions stigmatization among persons who completed predictive Huntington's disease (HD). Using semi‐structured interviews...

10.1002/ajmg.b.30600 article EN American Journal of Medical Genetics Part B Neuropsychiatric Genetics 2007-10-19

Genetic discrimination-defined as the denial of rights, privileges, or opportunities other adverse treatment based solely on genetic information (including family history)-is an important concern to patients, healthcare professionals, lawmakers, and members at risk for carrying a deleterious gene. Data from United States, Canada, Australia were collected 433 individuals Huntington disease (HD) who have tested either positive negative gene that causes HD affected 50% developing disorder but...

10.1002/ajmg.b.31079 article EN American Journal of Medical Genetics Part B Neuropsychiatric Genetics 2010-03-31

Abstract Genetic discrimination may be experienced in the day‐to‐day lives of people at risk for Huntington disease (HD), encompassing occurrences workplace, when seeking insurance, within social relationships, and during other daily encounters. At‐risk individuals who have tested either positive or negative genetic expansion that causes HD, as well at‐risk persons with a 50% chance developing disorder but not had DNA testing completed International RESPOND‐HD (I‐RESPOND‐HD) survey. One...

10.1002/ajmg.b.31080 article EN American Journal of Medical Genetics Part B Neuropsychiatric Genetics 2010-04-05

Genome-wide methylation arrays are increasingly used tools in studies of complex medical disorders. Because their expense and potential utility to the scientific community, current federal policy dictates that data from these arrays, like those genome-wide genotyping be deposited publicly available databases. Unlike information, access expression is not restricted. An underlying supposition nonrestricted belief protected health personal identifying information cannot simultaneously extracted...

10.1186/1868-7083-6-28 article EN cc-by Clinical Epigenetics 2014-11-19

10.1097/gim.0b013e31818ca4e7 article EN publisher-specific-oa Genetics in Medicine 2008-12-01

Aims: This study examines elements of genetic discrimination among an at-risk, clinically undiagnosed Huntington's disease (HD) population. Methods: Sixty at-risk individuals, either positive or negative for the HD mutation, completed a survey regarding their experiences discrimination, adverse and unfair treatment, knowledge about existing laws policies surrounding discrimination. Results: eight percent participants reported feeling "Great benefit" from knowing test results. Reported...

10.1089/gtmb.2012.0288 article EN Genetic Testing and Molecular Biomarkers 2013-01-04

A family history of Huntington disease (HD) or receiving results HD predictive genetic testing can influence individual well-being, relationships, and social interactions in positive negative ways. The aim this study was to examine benefits reported by people with an those who have undergone testing, as well the personal variables associated perceived benefits.

10.1089/gtmb.2010.0065 article EN Genetic Testing and Molecular Biomarkers 2010-08-19

10.1007/s10912-014-9306-4 article EN Journal of Medical Humanities 2014-10-06

Epigenetic testing is one of the most significant new technologies to provide insight into behavioral and environmental factors that influence development reconfiguration human genetic code. This technology allows us identify structural changes in genome occur due exposure a wide variety substances including alcohol, tobacco, cannabis. The information gained can be used promote health but it also raises ethical, legal, social issues. As society progresses understanding epigenetic mechanisms...

10.1002/bsl.2204 article EN Behavioral Sciences & the Law 2015-09-11

Epigenetic research has brought several important technological achievements, including identifying epigenetic clocks and signatures, developing editing. The potential military applications of such technologies we discuss are stratifying soldiers' health, exposure to trauma using testing, information about biological clocks, confirming child minor status inducing modifications in soldiers. These uses could become a reality. This article presents comprehensive literature review, analysis by...

10.1093/jlb/lsad034 article EN cc-by Journal of Law and the Biosciences 2023-07-01

10.1016/j.xjep.2015.07.023 article EN Journal of Interprofessional Education & Practice 2015-06-01

<h3>Background</h3> Although correlation between CAG repeat length and age of HD onset is well known, improved prediction would be advantageous for clinical trial sample enrichment genetic counselling. <h3>Aims</h3> To examine the predictive utility genetic, demographic, motor, cognitive, psychiatric, functional imaging measures predicting conversion to manifest HD. <h3>Methods</h3> Over 1000 research participants with gene mutation from 33 worldwide sites were followed up 10 years...

10.1136/jnnp-2014-309032.184 article EN Journal of Neurology Neurosurgery & Psychiatry 2014-09-01
Coming Soon ...